Arg(15,20,21)-Leu(17)- vasoactive intestinal peptide-GRR

Subscribe to Selected New Research on Arg(15,20,21)-Leu(17)- vasoactive intestinal peptide-GRR

2 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: putative drug delivery system for VIP therapy

Also Known As:

vasoactive intestinal peptide-GRR, Arg(15,20,21)-Leu(17)-; (R(15,20,21),L(17))-VIP-GRR; 15,20,21-Arg-17-Leu-VIP-GRR; IK 312532; IK-312532; IK312532; VIP-GRR, arginyl(15,20,21)-leucyl(17)-

Bio-Agent Context: Research Results

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 12/15/2004 - "Taken together with our previous report showing that IK312532 has long-acting relaxant activity in the lung, IK312532 may be a potential candidate for drug treatment of asthma and COPD." 12/15/2004 - "In the present study, we investigated the effect of VIP and its related peptides including long-acting VIP derivative (IK312532) and PACAP27 on the cytotoxicity of cigarette smoke extract (CSE), a causative factor of chronic obstructive pulmonary disease (COPD), in rat alveolar L2 cells" Get all the results and reference details, order at left...
2.	Asthma (Bronchial Asthma) 12/15/2004 - "Taken together with our previous report showing that IK312532 has long-acting relaxant activity in the lung, IK312532 may be a potential candidate for drug treatment of asthma and COPD." 12/15/2004 - "Thus, the formulation of IK312532 as DPI may be a pharmacologically useful drug delivery system for the therapy of pulmonary diseases such as asthma." Get all the results and reference details, order at left...
3.	Lung Diseases (Lung Disease) 12/15/2004 - "Thus, the formulation of IK312532 as DPI may be a pharmacologically useful drug delivery system for the therapy of pulmonary diseases such as asthma." Get all the results and reference details, order at left...
3 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
2.	Smoke
3.	Peptides
4.	(3,4-dihydroxyphenylamino)-2-imidazoline (DPI)
4 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>